N-Terminal B-type Natriuretic Peptide in Heart Failure

Heart Fail Clin. 2018 Jan;14(1):27-39. doi: 10.1016/j.hfc.2017.08.004.

Abstract

Plasma amino-terminal pro-B-type natriuretic peptide (NT-proBNP) is a guideline-mandated biomarker in heart failure (HF). Used as an inclusion criterion for therapeutic trials, NT-proBNP enriches trial populations and is a valid surrogate endpoint. Its diagnostic performance is best validated in acute decompensated HF (ADHF). NT-proBNP offers prognostic information independent of standard clinical predictors and refines risk stratification. With the advent of combined angiotensin 2 type 1 receptor blockade and neprilysin inhibition (ARNI) NT-proBNP retains its relationship to cardiac status and is the marker of choice in assessment of possible ADHF and in serial monitoring of HF patients receiving ARNI treatment.

Keywords: Diagnosis; Heart failure; Monitoring; NT-proBNP; Prognosis.

Publication types

  • Review

MeSH terms

  • Biomarkers / blood
  • Heart Failure / blood*
  • Humans
  • Natriuretic Peptide, Brain / blood*
  • Peptide Fragments / blood*
  • Prognosis
  • Protein Precursors

Substances

  • Biomarkers
  • Peptide Fragments
  • Protein Precursors
  • pro-brain natriuretic peptide (1-76)
  • Natriuretic Peptide, Brain